D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a single site, open-label, feasibility study of cognitive behavioral therapy with
exposure and response prevention (CBT/ERP) adding the augmentation of D-cycloserine (DCS) for
adolescents ages 12-17 with Obsessive Compulsive Disorder (OCD) who are partial or
non-responders to first line treatments of CBT or pharmacotherapy.